心肌纤维化预测心脏电子装置植入后室性心律失常与猝死
该前瞻性研究纳入700例心脏植入式电子装置(CIED)患者,用心脏磁共振评估心肌纤维化视觉评估(MFVA)和灰区纤维化(GZF)质量,中位随访6.93年。MFVA可排除猝死风险(阴性预测值100%),GZF5SD质量>17g者猝死和心律失常终点风险最高,而LVEF不能预测任一终点。
要点
- MFVA阴性者猝死风险极低(阴性预测值100%),可辅助排除高危患者。
- GZF5SD质量>17g与猝死和室性心律失常风险显著升高相关。
- LVEF不能预测CIED植入后猝死或室性心律失常终点。
核心结论
- 在CIED植入者中,MFVA可排除猝死风险并几乎排除室性心律失常。
- 量化GZF5SD质量对猝死和心律失常终点有额外预测价值。
研究设计与样本
- 前瞻性研究,纳入700例CIED植入患者,年龄68.0±12.0岁。
- 用心脏磁共振量化总纤维化和GZF质量,评估与猝死及心律失常终点的关系。
主要发现
- 中位随访6.93年(IQR 5.82-9.32年),27例(3.85%)发生猝死,121例(17.3%)达到心律失常终点。
- MFVA预测猝死(HR 26.3;95%CI 3.7-3337;阴性预测值100%)。
- 竞争风险分析中MFVA预测心律失常终点(subdistribution HR 19.9;95%CI 6.4-61.9;阴性预测值98.6%)。
- GZF5SD质量>17g与最高猝死风险相关(HR 44.6;95%CI 6.12-5685),心律失常终点subdistribution HR 30.3(95%CI 9.6-95.8)。
- 将GZF5SD质量加入MFVA使猝死重分类39%、心律失常终点重分类50.2%;LVEF未预测任一终点。
关键数值与推荐
- MFVA阴性对猝死阴性预测值100%,对心律失常终点阴性预测值98.6%。
- GZF5SD质量>17g者猝死HR 44.6(95%CI 6.12-5685),心律失常终点subdistribution HR 30.3(95%CI 9.6-95.8)。
临床怎么用
- CIED植入后可考虑用磁共振评估MFVA和GZF5SD质量辅助猝死和室性心律失常风险分层。
- MFVA阴性者猝死和室性心律失常风险极低,或可减少不必要的预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasing evidence supports a link between myocardial fibrosis (MF) and ventricular arrhythmias. OBJECTIVES: The purpose of this study was to determine whether presence of myocardial fibrosis on visual assessment (MFVA) and gray zone fibrosis (GZF) mass predicts sudden cardiac death (SCD) and ventricular fibrillation/sustained ventricular tachycardia after cardiac implantable electronic device (CIED) implantation. METHODS: In this prospective study, total fibrosis and GZF mass, quantified using cardiovascular magnetic resonance, was assessed in relation to the primary endpoint of SCD and the secondary, arrhythmic endpoint of SCD or ventricular arrhythmias after CIED implantation. RESULTS: Among 700 patients (age 68.0 ± 12.0 years), 27 (3.85%) experienced a SCD and 121 (17.3%) met the arrhythmic endpoint over median 6.93 years (IQR: 5.82-9.32 years). MFVA predicted SCD (HR: 26.3; 95% CI: 3.7-3,337; negative predictive value: 100%). In competing risk analyses, MFVA also predicted the arrhythmic endpoint (subdistribution HR: 19.9; 95% CI: 6.4-61.9; negative predictive value: 98.6%). Compared with no MFVA, a GZF mass measured with the 5SD method (GZF5SD) >17 g was associated with highest risk of SCD (HR: 44.6; 95% CI: 6.12-5,685) and the arrhythmic endpoint (subdistribution HR: 30.3; 95% CI: 9.6-95.8). Adding GZF5SD mass to MFVA led to reclassification of 39% for SCD and 50.2% for the arrhythmic endpoint. In contrast, LVEF did not predict either endpoint. CONCLUSIONS: In CIED recipients, MFVA excluded patients at risk of SCD and virtually excluded ventricular arrhythmias. Quantified GZF5SD mass added predictive value in relation to SCD and the arrhythmic endpoint.
引用
- Leyva F, Zegard A, Okafor O, et al. Myocardial Fibrosis Predicts Ventricular Arrhythmias and Sudden Death After Cardiac Electronic Device Implantation. J Am Coll Cardiol. 2022. PMID: 35177196. doi:10.1016/j.jacc.2021.11.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。